Bio-Path Holdings, Inc. Announces “At-the-Market” Offering with Cantor Fitzgerald

June 25, 2015 – HOUSTON, TX – Bio-Path Holdings, Inc., (NASDAQ: BPTH) (“Bio-Path”), a biotechnology company developing a liposomal delivery technology for nucleic acid cancer drugs, today announced it has established an “at-the-market” (“ATM”) program through which it may offer and sell up to $25 million of common stock from time to time, at Bio-Path’s discretion, through Cantor Fitzgerald & Co., acting as sales agent. Sales of Bio-Path common stock under the ATM program may be made directly on or through the Nasdaq Capital Market, among other methods

Maxim Group acted as a financial advisor to Bio-Path Holdings, Inc.’s at-the-market offering

This entry was posted in Investment Banking News: Q2- 2015. Bookmark the permalink.